{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:08:11Z","timestamp":1790251691378,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[1998,9,1]],"date-time":"1998-09-01T00:00:00Z","timestamp":904608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The mechanisms by which interleukin-12 (IL-12) exerts antitumor effects have been difficult to dissect. In this study, we examined the potential contribution of the chemokines interferon\u03b3-inducible protein-10 (IP-10) and Mig to the antitumor effects of IL-12. Using an athymic mouse model, local inoculations with IL-12 consistently produced tumor size reductions associated with characteristic tumor necrosis and vascular damage. These effects were indistinguishable from those produced by IP-10 or Mig injected locally in the same tumor model. Local and systemic treatment with IL-12 was associated with expression of the interferon-\u03b3 (IFN-\u03b3), IP-10, and Mig genes and proteins in the tumor. Levels of IP-10 and Mig expression in the tumor, the liver, and the kidney were inversely correlated with tumor size. Administration in vivo of neutralizing antibodies to IP-10 and Mig reduced substantially the antitumor effects of IL-12 inoculated locally into the tumors. These results support the notion that IP-10 and Mig contribute to the antitumor effects of IL-12 through their inhibitory effects on tumor vasculature. J. Leukoc. Biol. 64: 384\u2013392; 1998.<\/jats:p>","DOI":"10.1002\/jlb.64.3.384","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T18:56:03Z","timestamp":1515783363000},"page":"384-392","source":"Crossref","is-referenced-by-count":110,"title":["Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12"],"prefix":"10.1093","volume":"64","author":[{"given":"Chiharu","family":"Kanegane","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Sgadari","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kanegane","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Hematopathology Section, National Cancer Institute , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yao","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam","family":"Gupta","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M","family":"Farber","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Investigation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liao","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Investigation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"PharMingen , San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Tosato","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration , Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,9,1]]},"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjlb.64.3.384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/64\/3\/384\/49737000\/jlb0384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/64\/3\/384\/49737000\/jlb0384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T05:22:39Z","timestamp":1680672159000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/64\/3\/384\/6976788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[1998,9,1]]},"published-print":{"date-parts":[[1998,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jlb.64.3.384","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,9]]},"published":{"date-parts":[[1998,9,1]]}}}